Value of tumour marker S-100B in melanoma patients: A comparison to 18F-FDG PET and clinical data

NuklearMedizin

Volumn 41, Issue 3, 2002, Pages 143-147

  Reinhardt, Michael J ^a   Kensy, J ^a   Frohmann, J P ^a   Willkomm, P ^a   Reinhold, U ^a   Grunwald F ^a   Biersack, H J ^a   Bender, H ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

18F FDG PET; Malignant melanoma; S 100B protein

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PROTEIN S100B; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC VALUE; DRUG UPTAKE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNORADIOMETRIC ASSAY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; MELANOMA; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; THICKNESS;

EID: 0036084706     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1623884     Document Type: Article

References (33)

1. Serum S-100 protein: A potentially useful prognostic marker in cutaneous melanoma
2. S-100 protein-negative malignant melanoma: Fact or fiction? A light-microscopic and immunohistochemical study
3. Cutaneous melanoma
4. Cutaneous melanoma
5. Value of 18-fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma
6. Thickness, cross-sectional areas and depth of melanoma in the prognosis of cutaneous melanoma
7. Tumor progression and the nature of cancer
8. Late recurrence of malignant melanoma
9. The natural break points for primary-tumor thickness in clinical stage I melanoma
10. 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: A comparison of ultrasonographic and radiological methods of diagnosis
11. Comparison of S 100 protein and MIA protein as serum marker for malignant melanoma
12. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma
13. Etiology, epidemiology, risk factors, and public health issues of melanoma
14. Clinical significance of serum S-100 in metastatic malignant melanoma
15. Prognostic value of serum analyses of S-100 protein beta in malignant melanoma
16. Serum S-100 - A marker for disease monitoring in metastatic melanoma
17. Surface antigens of melanocytes and melanomas. Markers of melanoma differentiation and melanoma subsets
18. Comparison of two prognostic markers for malignant melanoma: MIA and S 100 beta
19. S-100 protein in peripheral blood: A marker for melanoma metastases: A prospective 2-center study of 570 patients with melanoma
20. Development of invasive and growth factor independent cell variants from primary human melanomas
21. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma. A pilot study
22. Familial atypical multiple mole-melanoma syndrome
23. Serum S-100B protein as prognostic marker in malignant cutaneous melanoma
24. Diagnostic accuracy and predictive value of tumor-associated antigen S 100 in malignant melanomas: Validation by whole body FDG-PET and conventional diagnostics
25. Malignant melanoma staging using whole-body positron emission tomography
26. FDG-PET for clinical use
27. Detection of melanoma metastases with Tc-99m-tetrofosmin
28. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients
29. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients
30. Malignant melanoma: Staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose
31. Planar coincidence scintigraphy and PET in staging malignant melanoma
32. Prognostic value of serum analyses of S-100 beta protein in malignant melanoma
33. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma